Formononetin improved healthspan via the P53/P21/CDK4 pathway in SAMP8 mice and DAF-16/SKN-1 signaling pathway in C.elegans
Year: 2026
Type: article
Abstract: Objective To investigate the healthy aging effects of Formononetin and its underlying molecular mechanisms. Methods SAMP8 mice were administered Formononetin (4, 8, 16 mg/kg, po) for 5 months. Behavioral tests were performed in 9-month-old mice, followed by histopathology. 5-methylcytosine (5-mC) level in the brain were detected by immunofluorescence, aging-related protein expression was measured by Western blot. In C . elegans , the lifespan, stress resistance, and aging-related gene expressions were assessed. Mutant strains ( daf-16 and skn-1 ) were used to verify pathway dependency. Results Formononetin dose-dependently ameliorated cognitive deficits, anxiety-like behaviors, and motor decline in SAMP8 mice, attenuated neuronal damage in the hippocampal CA1, DG and cerebral cortex, reversed 5-mC level, downregulated protein expression of P53, P21, while upregulated CDK4 and Nrf2. In C . elegans , Formononetin (37.30 μmol/L) significantly extended lifespan under normal, thermal stress, and oxidative stress conditions, improved locomotion, reduced lipofuscin accumulation, increased total SOD activity, and upregulated skn-1, sir-2.1, daf-16 and sod-3 mRNA. No lifespan extension was observed in daf-16 or skn-1 mutants. Conclusion Formononetin effectively attenuated cognitive deficits, ameliorated neuronal damage and increased 5-mC level, possibly via regulated P53, P21, CDK4 and Nrf2 protein expression in the brain of SAMP8 mice. In C. elegans , Formononetin extended lifespan, increased stress resistance, and improved locomotion and lipofuscin accumulation, possibly via regulated expression of DAF-16 and SKN-1.
Source: Frontiers in Pharmacology
Institution: Zunyi Medical University
Language: English
Subfield: Aging
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,801
Awards: G5595043203, G7821027087
OpenAlex ID: W7214072820
